Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Techne (TECH) Change in Receivables (2016 - 2025)

Historic Change in Receivables for Bio-Techne (TECH) over the last 17 years, with Q4 2025 value amounting to -$941000.0.

  • Bio-Techne's Change in Receivables fell 25104.33% to -$941000.0 in Q4 2025 from the same period last year, while for Dec 2025 it was -$36.5 million, marking a year-over-year decrease of 28330.32%. This contributed to the annual value of -$34.1 million for FY2025, which is 26623.0% down from last year.
  • According to the latest figures from Q4 2025, Bio-Techne's Change in Receivables is -$941000.0, which was down 25104.33% from -$22.4 million recorded in Q3 2025.
  • Bio-Techne's Change in Receivables' 5-year high stood at $51.6 million during Q1 2022, with a 5-year trough of -$28.9 million in Q2 2025.
  • For the 5-year period, Bio-Techne's Change in Receivables averaged around $2.7 million, with its median value being $357500.0 (2023).
  • As far as peak fluctuations go, Bio-Techne's Change in Receivables crashed by 57662.91% in 2022, and later skyrocketed by 1938043.48% in 2024.
  • Over the past 5 years, Bio-Techne's Change in Receivables (Quarter) stood at $5.7 million in 2021, then increased by 3.5% to $5.9 million in 2022, then crashed by 180.1% to -$4.7 million in 2023, then soared by 113.16% to $623000.0 in 2024, then plummeted by 251.04% to -$941000.0 in 2025.
  • Its Change in Receivables stands at -$941000.0 for Q4 2025, versus -$22.4 million for Q3 2025 and -$28.9 million for Q2 2025.